Dexamethasone sodium phosphate Visulex - Aciont

Drug Profile

Dexamethasone sodium phosphate Visulex - Aciont

Alternative Names: Dexamethasone sodium phosphate - Visulex™; DSP-Visulex™

Latest Information Update: 17 Dec 2014

Price : $50

At a glance

  • Originator Aciont
  • Class Anti-inflammatories; Antiemetics; Antineoplastics; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Uveitis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 17 Dec 2014 Aciont has patent protection for Visulex in USA
  • 16 Dec 2014 Dexamethasone sodium phosphate Visulex - Aciont is available for licensing as of 16 Dec 2014. http://www.aciont.com/product_pipeline/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top